|
Jul 31
|
AIM ImmunoTech Announces Closing of $8.0 Million Public Offering
|
|
Jul 29
|
AIM ImmunoTech Announces Pricing of $8.0 Million Public Offering
|
|
Jul 28
|
AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
|
|
Jul 18
|
JTC Team Announces Participating Line Up for the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference
|
|
Jul 2
|
AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies
|
|
Jun 20
|
AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders’ Equity Requirements
|
|
Apr 4
|
AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal
|
|
Mar 11
|
AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
|
|
Jan 17
|
AIM ImmunoTech (AIM) Upgraded to Strong Buy: What Does It Mean for the Stock?
|
|
Jan 15
|
AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones
|
|
Oct 9
|
AIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC
|
|
Sep 30
|
AIM ImmunoTech Announces Pricing of $1.26 Million Registered Direct Offering
|
|
Sep 27
|
AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment
|
|
Aug 20
|
AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
|
|
Aug 16
|
AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update
|
|
Jul 29
|
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
|
|
Jul 24
|
AIM Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination Therapy
|
|
Jun 10
|
AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference
|
|
May 20
|
AIM ImmunoTech to Participate in Two Upcoming Investor Conferences
|
|
Mar 15
|
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity
|